Pulse Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 56
- Market Cap
- -
- Introduction
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Novel Contact Force-Sensing Pulsed Field Ablation Catheter Shows Promise in Paroxysmal AF Treatment
• First-in-human data demonstrates 100% acute procedural success with Omnypulse, a novel contact force-sensing pulsed field ablation catheter for paroxysmal atrial fibrillation treatment.
• The catheter showed promising durability with 84.5% of pulmonary veins remaining isolated at 3-month follow-up, with only four non-device-related adverse events reported.
• Comparable technology from Kardium (Globe) demonstrated 78% freedom from treatment failure at 12 months with 95% pulmonary vein isolation durability, suggesting significant advancements in AF ablation technology.
Pulse Biosciences Showcases Nanosecond PFA Technology at AF Symposium 2025
Pulse Biosciences' innovative Nanosecond Pulsed Field Ablation (nsPFA) technology, particularly its nsPFA 360° Cardiac Catheter, will be highlighted at the 30th Annual AF Symposium 2025. The technology, designed for atrial fibrillation ablation, will be featured in a late-breaking clinical science session and a live case transmission, showcasing its clinical benefits and workflow efficiency.
© Copyright 2025. All Rights Reserved by MedPath